146 related articles for article (PubMed ID: 32454885)
1. Fusion of FDG-PET Image and Clinical Features for Prediction of Lung Metastasis in Soft Tissue Sarcomas.
Deng J; Zeng W; Shi Y; Kong W; Guo S
Comput Math Methods Med; 2020; 2020():8153295. PubMed ID: 32454885
[TBL] [Abstract][Full Text] [Related]
2. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities.
Vallières M; Freeman CR; Skamene SR; El Naqa I
Phys Med Biol; 2015 Jul; 60(14):5471-96. PubMed ID: 26119045
[TBL] [Abstract][Full Text] [Related]
3. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
[No Abstract] [Full Text] [Related]
4. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.
Fendler WP; Chalkidis RP; Ilhan H; Knösel T; Herrmann K; Issels RD; Bartenstein P; Cyran CC; Lindner LH; Hacker M
Eur Radiol; 2015 Aug; 25(8):2214-21. PubMed ID: 25693667
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
[TBL] [Abstract][Full Text] [Related]
7. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of
Kassem TW; Abdelaziz O; Emad-Eldin S
Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
[TBL] [Abstract][Full Text] [Related]
9.
Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
[TBL] [Abstract][Full Text] [Related]
10. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?
Hain SF; O'Doherty MJ; Bingham J; Chinyama C; Smith MA
Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167
[TBL] [Abstract][Full Text] [Related]
11. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.
Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495
[TBL] [Abstract][Full Text] [Related]
12. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
13. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment
Ahn HK; Lee H; Kim SG; Hyun SH
Clin Radiol; 2019 Jun; 74(6):467-473. PubMed ID: 30898382
[TBL] [Abstract][Full Text] [Related]
15. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas.
Nagamatsu A; Umesaki N; Li L; Tanaka T
Oncol Rep; 2010 Apr; 23(4):1069-76. PubMed ID: 20204293
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
17. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
18. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
19. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]